MedMind Technology Co., Ltd. is an innovative company in the field of artificial intelligence healthcare. Leveraging its independently developed core technologies in deep learning and holographic image analysis, we specializes in the intelligent analysis of large medical imaging datasets.

As leading company in auto-contouring the clinical target volumes (CTVs), we are focusing on major types of cancers treatment, including nasopharyngeal carcinoma, breast cancer, rectal cancer, cervical cancer, colorectal cancer, and esophageal cancer. Additionally, we offer RT-Mind-AI, a product that outlines over 120 Organ-at-Risk throughout the body. The clinical research has been published in international journals such as Radiology, Radiotherapy and Oncology, Medical Physics etc. Our vision is to provide a one-stop digital and intelligent radiotherapy solution for tumor radiotherapy, ultimately achieving automation of the entire radiotherapy process. Therefore, we provide a series of intelligent radiotherapy products, including the oncology information system RT-Link, radiotherapy dose verification system RT-PlanQA, radiotherapy research and follow-up system RT-Research, and remote radiotherapy collaboration system RT-Cloud.

With FDA clearance in the United States, our product has been installed and applied in over 360 hospitals worldwide, improving the level of homogenization and intelligence in radiotherapy.